Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,227 shares of the biopharmaceutical company’s stock after acquiring an additional 183 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,586,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $28,000. Private Wealth Management Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 39 shares during the period. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $707.51 on Monday. The firm has a market cap of $77.35 billion, a PE ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $696.12 and a 200-day simple moving average of $848.69. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $11.86 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.